Telix Pharmaceuticals Reports Strong H1 2026 Results
Key points
- Revenue of $477M, up 22% year-over-year
- Group gross margin of 55%, up 2% year-over-year
- Strategic collaboration with Regeneron for next-generation radiopharmaceuticals
- Completed refinancing of convertible bonds
- Positive operating cash flow of $23M
Full summary
Telix Pharmaceuticals Limited (ASX: TLX) announced its financial results for the half-year ended June 30, 2026. The company reported a 22% increase in group revenue to $477 million, with a gross margin of 55%, up 2% year-over-year. The Precision Medicine segment saw a 27% rise in revenue, driven by strong sales of Illuccix and Gozellix. The company also entered into a strategic collaboration with Regeneron and completed the refinancing of its convertible bonds. Telix reaffirmed its FY 2026 revenue guidance of $950 million to $970 million and established an 'at-the-market' facility to enhance access to its securities on the Nasdaq stock exchange.
Guidance
FY 2026 revenue and other income expected to be over $1 billion
Outlook
Telix expects to maintain strong momentum with multiple near-term catalysts, including progress in clinical and regulatory milestones.
Summary generated by a large language model. Please interpret with care.